The use of recombinant human granulocyte macrophage colony-stimulating factor in autologous bone marrow transplantation.
Phase I, II trials indicate that Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF), stimulates recovery of neutrophils following myelosuppressive chemoradiotherapy. In Seattle it was administered to patients undergoing autologous bone marrow transplant (ABMT) for lymphoid malignancy. The data indicate that rhGM-CSF was well tolerated and associated with earlier neutrophil recovery, fewer infections and shorter initial hospital duration. Survival was not improved, however, less regimen-related toxicity was observed. Studies in patients with marrow graft failure are strongly suggestive of improved survival and rhGM-CSF is recommended for therapy in those patients. Although numbers were small, results in pediatric patients were not significantly different than results in adults.
Nemunaitis
J J
JJ
Fred Hutchinson Cancer Research Center, Seattle, WA.
Singer
J W
JW
Sanders
J E
JE
D000293:Adolescent; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000187:drug effects; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007938:Leukemia / Q000188:drug therapy / Q000453:epidemiology / Q000601:surgery; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D014182:Transplantation, Autologous
D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor